A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography: Journal of Cardiovascular Computed Tomography

S.J. Al'Aref, A. Su, H. Gransar, A.R. van Rosendael, A. Rizvi, D.S. Berman, T.Q. Callister, A. DeLago, M. Hadamitzky, J. Hausleiter, M.H. Al-Mallah, M.J. Budoff, P.A. Kaufmann, G.L. Raff, K. Chinnaiyan, F. Cademartiri, E. Maffei, T.C. Villines, Y.-J. Kim, J. LeipsicG. Feuchtner, G. Pontone, D. Andreini, H. Marques, P. de Araújo Gonçalves, R. Rubinshtein, S. Achenbach, H.-J. Chang, B.J.W. Chow, R. Cury, Y. Lu, J.J. Bax, E.C. Jones, J.M. Peña, L.J. Shaw, J.K. Min, F.Y. Lin

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Non-statin therapy (NST)is used as second-line treatment when statin monotherapy is inadequate or poorly tolerated. Objective: To determine the association of NST with plaque composition, alone or in combination with statins, in patients undergoing coronary computed tomography angiography (coronary CTA). Methods: From the multicenter CONFIRM registry, we analyzed individuals who underwent coronary CTA with known lipid-lowering therapy status and without prior coronary artery disease at baseline. We created a propensity score for being on NST, followed by stepwise multivariate linear regression, adjusting for the propensity score as well as risk factors, to determine the association between NST and the number of coronary artery segments with each plaque type (non-calcified (NCP), partially calcified (PCP)or calcified (CP))and segment stenosis score (SSS). Results: Of the 27,125 subjects in CONFIRM, 4,945 met the inclusion criteria; 371 (7.5%)took NST. At baseline, patients on NST had more prevalent risk factors and were more likely to be on concomitant cardiac medications. After multivariate and propensity score adjustment, NST was not associated with plaque composition: NCP (0.07 increase, 95% CI: −0.05, 0.20; p = 0.26), PCP (0.10 increase, 95% CI: −0.10, 0.31; p = 0.33), CP (0.18 increase, 95% CI: −0.10, 0.46; p = 0.21)or SSS (0.45 increase, 95% CI: −0.02,0.93; p = 0.06). The absence of an effect of NST on plaque type was not modified by statin use (p for interaction > 0.05 for all). Conclusion: In this cross-sectional study, non-statin therapy was not associated with differences in plaque composition as assessed by coronary CTA. © 2019
Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalJ. Cardiovasc. Comput. Tomogr.
Volume13
Issue number2
DOIs
Publication statusPublished - 2019

Keywords

  • Coronary computed tomography angiography
  • Coronary plaque composition
  • Ezetimibe
  • Fibrate
  • Niacin
  • Non-statin therapy
  • antilipemic agent
  • biological marker
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • lipid
  • adult
  • Article
  • computed tomographic angiography
  • coronary angiography
  • coronary artery atherosclerosis
  • coronary artery calcium score
  • coronary risk
  • cross-sectional study
  • female
  • human
  • major clinical study
  • male
  • middle aged
  • priority journal
  • propensity score
  • aged
  • Asia
  • atherosclerotic plaque
  • blood
  • clinical trial
  • combination drug therapy
  • coronary artery disease
  • coronary artery obstruction
  • coronary blood vessel
  • diagnostic imaging
  • dyslipidemia
  • Europe
  • multicenter study
  • North America
  • pathology
  • predictive value
  • prevalence
  • procedures
  • register
  • risk factor
  • Aged
  • Biomarkers
  • Computed Tomography Angiography
  • Coronary Angiography
  • Coronary Artery Disease
  • Coronary Stenosis
  • Coronary Vessels
  • Cross-Sectional Studies
  • Drug Therapy, Combination
  • Dyslipidemias
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Lipids
  • Male
  • Middle Aged
  • Plaque, Atherosclerotic
  • Predictive Value of Tests
  • Prevalence
  • Registries
  • Risk Factors

Fingerprint

Dive into the research topics of 'A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography: Journal of Cardiovascular Computed Tomography'. Together they form a unique fingerprint.

Cite this